Ratings Absci Corporation

Equities

ABSI

US00091E1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
4.97 ^USD	-6.05%		-18.32%	+18.33%

Mar. 21	Earnings Flash (ABSI) ABSCI CORPORATION Reports Q4 Revenue $338,000	MT
Mar. 21	Absci Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ABSCI CORPORATION	+18.33%	561M	C-
IQVIA HOLDINGS INC.	-1.82%	41.35B	B
LONZA GROUP AG	+42.78%	40.38B	A
MODERNA, INC.	+2.56%	39.05B	B-
CELLTRION, INC.	-12.11%	26.67B	C
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B	B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B	C+
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes